Loading events...
An entire session at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda was devoted to the PURPOSE 1 and PURPOSE 2 studies of the six-monthly injectable PrEP drug lenacapavir, which reflects its importance as a step forward in HIV prevention. Lenacapavir for PrEP has recently received positive decisions by drug regulators in the US and Europe . During the conference, the World Health Organization issued guidelines recommending it .
Wednesday, July 30, 2025
Kigali, Rwanda
An entire session at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda was devoted to the PURPOSE 1 and PURPOSE 2 studies of the six-monthly injectable PrEP drug lenacapavir, which reflects its importance as a step forward in HIV prevention. Lenacapavir for PrEP has recently received positive decisions by drug regulators in the US and Europe . During the conference, the World Health Organization issued guidelines recommending it .
Receive curated event recommendations based on your interests.
See how WebMobi helps you manage registration, check-in, and analytics.
Request a DemoOr start free trial →Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions takes place on Wednesday, July 30, 2025.
Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions is held in Kigali, Rwanda.
Pricing information is available on the event website.
Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions is designed for healthcare professionals looking to network, learn, and discover new opportunities.
Get curated B2B events, AI-powered insights, and industry trends delivered to your inbox